<International Circulation>:  Are there any agents on the horizon that may give you cause to pause?

　 《国际循环》：即将上市的药物中是否有是您犹豫不决的呢？

　　Professor Ray: Any drug that works on the incretin pathway appears to have beneficial effects on other factors like weight， for example， resulting in either weight neutrality or weight loss which is a major problem with most hyperglycemic agents we have and at least on lipid profile and maybe on blood pressure there may be slight improvements as well. Because we know the etiology of heart failure is also related to many of the risk factors for atherosclerosis， a combination of those effects may contribute. That doesn’t answer the glucose question though and is more of a strategy， as the drug may have multiple interventions.

    Ray教授:所有通过肠降血糖素途径的药物都对减少体重等其他危险因素有益，例如，目前大部分降糖药都存在导致体重减轻或只能保持体重的问题，对于血脂和血压的改善也微乎其微。我们已经知道心力衰竭的病因与动脉粥样硬化或者某些并存的危险因素有关，药物具有多方面的干预作用。但这并不能解决血糖的问题，它与治疗策略制定的关系更大